• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Gastroenterology

FDA approves dostarlimab (Jemperli) for certain patients with locally advanced rectal cancer

byChristian Shannon, MD, MSc, MPAffandMarc Succi, MD
October 29, 2026
in Gastroenterology, Oncology, Pharma, Surgery
Reading Time: 3 mins read
An illustration depicting the colon with IV bags on either side, symbolizing sequential therapy paths in colorectal cancer treatment.
Share on FacebookShare on TwitterShare on LinkedIn

1. Interim results from the phase 2 AZUR-1 trial have demonstrated that at a median follow-up of 2 years. nearly 75% of patients did not require surgery, radiotherapy, or chemotherapy after a 6-month regimen of Jemperli.

2. Up to 3% of stage II or stage III locally advanced rectal cancers exhibit traits that would qualify them for treatment with the new immunotherapy Jemperli, which would allow patients to avoid more invasive treatments.

Evidence Rating Level: 1 (Excellent)

Study Rundown: A new immunotherapy dostarlimab-gxly (Jemperli) has been approved by the US Food and Drug Administration 4 months ahead of schedule for some patients with stage II or stage III locally advanced rectal cancer whose tumors have mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). Based on current studies, approximately 3% of locally advanced rectal cancers are either dMMR or MSI-H, which are markers for tumors that have errors in their inherent DNA repair systems. These markers can now be tested by an FDA-authorized test. Jemperli works by targeting the protein PD-1 on immune cells in order to block cancer cells from shielding themselves from the body’s natural defense mechanisms. Early results from the phase 2 trial AZUR-1 evaluated use of Jemperli alone in 154 patients with previously untreated locally advanced rectal cancer found to have either dMMR or MSI-H. Each patient received nine doses of the immunotherapy every 3 weeks for a total of 6 months. At a median follow-up greater than years, nearly three quarters had not needed additional surgery, chemotherapy, or radiotherapy. A previous smaller study conducted at Memorial Sloan Kettering Cancer Center had evaluated 50 similar patients, and 93% of these patients had no detectable signs of cancer for at least a year after Jemperli treatment. More research needs to be done into the side effects of Jemperli, as well as longer follow-up with patients to establish longevity of treatment results.

Click here to read more about the AZUR-1 trial in the Annals of Oncology

Relevant Reading FDA press release: FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery | FDA

RELATED REPORTS

FDA Approves First DNA Medicine to Reduce Repeat Airway Surgeries

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

In-Depth [clinical trial]: Adult patients with stage II/III locally advanced rectal cancer found to have positive dMMR or MSI-H status were eligible for enrollment in the international, multicenter single-arm phase 2 study. Patients were given dostarlimab 500mg intravenously every 3 weeks for a total of 9 cycles, or until they had evidence of disease progression or intolerable toxicity. If patients achieved clinical complete response meaning there was no evidence of residual disease, they were then allowed to proceed with nonoperative management and were assessed for disease every 4 months for the first two months and then every 6 months for years 3-5. At time of interim analysis with a median follow-up of 26 months, 93% (n=143) of patients had no evidence of disease progression after treatment (dostarlimab ± standard of care), and 71% (n=110) achieved this outcome with dostarlimab alone. Four patients (3%) withdrew from the study, 5 patients (3%) died, and 2 patients (1%) experienced progressive disease after starting standard of care treatment. In addition, 94% of patients experienced a treatment-emergent adverse event. Immune-mediated adverse events occurred in 23% of patients, the most common of which was hypothyroidism which occurred in 8% of patients. In addition, 41% of patients reported improvement in global health status/quality of life on patient reported outcomes instruments (EORTC QLQ-C30, QLQ-CR29).

© 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: #cancercancerdostarlimabFDArectal cancer
Previous Post

In topline phase 3 results, retatrutide lowered A1C more and reduced weight more than semaglutide 2 mg at 80 weeks

Next Post

Care recommendations by large language models were associated with higher healthcare costs

RelatedReports

Collage for HPV: a preteen boy with a small bandage on his arm, a virus particle, a vaccine vial and a school backpack
Infectious Disease

FDA Approves First DNA Medicine to Reduce Repeat Airway Surgeries

November 10, 2026
A stylized illustration featuring the pancreas and kidney, with visual elements suggesting pain and chemotherapy effects, related to pancreatic cancer treatment.
Artificial Intelligence

Routine CT scans show steeper fat loss years before pancreatic cancer diagnosis

October 30, 2026
A calendar, a specimen jar, and a brush are depicted alongside a microscopic view of cervical cells, indicating cervical cancer screening.
All Specialties

An artificial intelligence system for human papillomavirus-positive dual stain cervical cancer screening reads p16-Ki67 slides

October 23, 2026
An illustration featuring a stomach, DNA helix, and a close-up of Helicobacter pylori bacteria, highlighting genetic susceptibility to gastric conditions.
Artificial Intelligence

Artificial intelligence capable of identifying uncommon gastrointestinal pathologies despite no targeted disease training

October 16, 2026
Next Post
A healthcare professional is depicted among images of technology, a vaccine vial, and a heart, symbolizing the integration of AI in medicine.

Care recommendations by large language models were associated with higher healthcare costs

A liver illustration accompanied by a vial representing hepatitis C treatment and RNA, highlighting research in hepatology.

In late-breaking phase 3 results, pozdeutinurad lowered serum urate through 12 months in patients with uncontrolled gout

The image shows an illustration of a knee joint, accompanied by a representation of an antibody, suggesting a focus on rheumatoid arthritis or psoriatic arthritis and its treatment.

Zemprocitinib sustained clinical responses through Week 76 in rheumatoid arthritis after inadequate response to biologic therapy

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Use of colchicine is not associated with reduced cardiovascular events among Chinese adults starting urate-lowering therapy
  • ARO-DIMER-PA can Significantly Lower LDL-C and Triglycerides in Patients with Mixed Hyperlipidemia
  • CCTA-guided PCI noninferior to IVUS-guided PCI for target-vessel failure
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.